Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A known ✓ | P35498 | 2/20 | 0.64 |
| ▸ | SCN2A known ✓ | Q99250 | 2/20 | 0.64 |
| ▸ | SCN3A known ✓ | Q9NY46 | 2/20 | 0.64 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.53 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.53 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.53 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.53 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.53 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.53 |
| ▸ | GHSR known ✓ | Q92847 | 1/20 | 0.53 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.97 |
| ▸ | THPO | P40225 | 2/20 | 0.97 |
| ▸ | MTOR | P42345 | 2/20 | 0.97 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.59 |
| ▸ | ABCC1 | P33527 | 4/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29361001 | 1.00 | KMT2A (1.00) | KMT2AMEN1PMP22CYP3A4CYP2D6 | |
| SCHEMBL2457928 | 0.99 | CYP3A4 (1.00) | KMT2AMEN1PMP22CYP3A4CYP2D6 | |
| SCHEMBL2173737 | 0.99 | CYP3A4 (1.00) | KMT2AMEN1PMP22CYP3A4CYP2D6 | |
| SCHEMBL2454357 | 0.99 | CYP3A4 (1.00) | KMT2AMEN1PMP22CYP3A4CYP2D6 | |
| Butanedione SCHEMBL8444179 | 0.95 | CYP3A4 (0.93) | KMT2AMEN1PMP22CYP3A4CYP2D6 | |
| SCHEMBL29759108 | 0.88 | CYP2D6 (0.80) | KMT2AMEN1PMP22CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL7883012 | 0.87 | MEN1 (0.77) | KMT2AMEN1PMP22CYP3A4CYP2D6 | |
| SCHEMBL9681943 | 0.84 | CYP3A4 (0.73) | KMT2AMEN1PMP22CYP3A4CYP2D6 | |
| SCHEMBL9680878 | 0.84 | CYP3A4 (0.73) | KMT2AMEN1PMP22CYP3A4CYP2D6 | |
| SCHEMBL9680837 | 0.84 | CYP3A4 (0.73) | KMT2AMEN1PMP22CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220152228-A1 | COMPOSITIONS AND METHODS FOR RADIOTHERAPY USING CHELATED RADIOTHERAPEUTIC AGENTS AND NON-TARGET TISSUE BLOCKADE | WASHINGTON UNIVERSITY (US) | 2022-05-19 | — | — | US | claimed |
| US-20200046693-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ZELLWEGER SPECTRUM DISORDER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-02-13 | — | — | US | claimed |
| US-20060194769-A1 | Small molecules that reduce fungal growth | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2006-08-31 | — | — | US | claimed |
| WO-2006081327-A2 | SMALL MOLECULES THAT REDUCE FUNGAL GROWTH | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2006-08-03 | — | — | WO | claimed |
| US-6337325-B1 | IMMUNOSUPRESSANTS, AUTOIMMUNE DISEASES, DERMATITIS, RHINITIS, UVEITIS, ANTIDIABETIC AGENTS, CYSTIC FIBROSIS OR LIVER FIBROSIS | HOECHST AKTIENGESELLSCHAFT (DE) | 2002-01-08 | — | — | US | claimed |
| US-12403104-B2 | Compounds and methods of promoting myelination | CASE WESTERN RESERVE UNIVERSITY (US) | 2025-09-02 | — | — | US | disclosed |
| US-12390423-B2 | Avocatin B for the treatment of diseases and conditions | SP NUTRACEUTICALS INC. (CA) | 2025-08-19 | — | — | US | disclosed |
| US-20230140688-A1 | AVOCATIN B FOR THE TREATMENT OF DISEASES AND CONDITIONS | SP NUTRACEUTICALS INC. (CA) | 2023-05-04 | — | — | US | disclosed |
| US-20230000798-A1 | COMPOUNDS AND METHODS OF PROMOTING MYELINATION | CASE WESTERN RESERVE UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| US-11344511-B2 | Compounds and methods of promoting myelination | CASE WESTERN RESERVE UNIVERSITY (US) | 2022-05-31 | — | — | US | disclosed |
| US-20220152228-A1 | COMPOSITIONS AND METHODS FOR RADIOTHERAPY USING CHELATED RADIOTHERAPEUTIC AGENTS AND NON-TARGET TISSUE BLOCKADE | WASHINGTON UNIVERSITY (US) | 2022-05-19 | — | — | US | disclosed |
| US-20210315885-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ZELLWEGER SPECTRUM DISORDER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-10-14 | — | — | US | disclosed |
| US-6107499-A | FACILITATING THE TRANSPORT OF A NEUROTRANSMITTER ACROSS THE BLOOD BRAIN BARRIER BY ADMINISTERING THE DRUG, A NEUROTRANSMITTER SUCH AS DOPAMINE COVALENTLY COUPLED TO A SINGLE, STRAIGHT-CHAINED FATTY ACID CARRIER MOLECULE | NEUROMEDICA, INC. (US) | 2000-08-22 | — | — | US | disclosed |
| US-5994392-A | PASSAGE OF DRUG THROUGH BLOOD BRAIN BARRIER | NEUROMEDICA, INC. (US) | 1999-11-30 | — | — | US | disclosed |
| EP-0784430-A1 | METHOD FOR REDUCING UNWANTED CELLULAR ADHESIONS | Zynaxis Inc. (US) | 1997-07-23 | — | — | EP | disclosed |
| WO-1997024459-A1 | METHOD FOR REDUCING UNWANTED CELLULAR ADHESIONS | PHANOS TECHNOLOGOES, INC. (US) | 1997-07-10 | — | — | WO | disclosed |
| WO-1996010912-A1 | METHOD FOR REDUCING UNWANTED CELLULAR ADHESIONS | ZYNAXIS, INC. (US) | 1996-04-18 | — | — | WO | disclosed |
| US-5480901-A | CONJUGATE OF LIPOPHILIC BINDING AGENT AND DRUG, QUATERNARY AMMONIUM COMPOUND, CONTROLLING TUMOR FORMATION | ZYNAXIS, INC. (US) | 1996-01-02 | — | — | US | disclosed |
| US-5409710-A | Foam cell drug delivery | ENDOCON, INC. (US) | 1995-04-25 | — | — | US | disclosed |
| WO-1994023706-A1 | FOAM CELL DRUG DELIVERY | ENDOCON, INC. (US) | 1994-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194769-A1 | Small molecules that reduce fungal growth | ERG28, DPM1, CYP51A1 | SCN1A 4561/4885SCN2A 4420/4885SCN3A 4548/4885 |
| US-12403104-B2 | Compounds and methods of promoting myelination | GMFG, MAG, SGMS1 | SCN1A 777/4885SCN2A 575/4885SCN3A 610/4885 |
| US-11344511-B2 | Compounds and methods of promoting myelination | GMFG, MAG, SGMS1 | SCN1A 777/4885SCN2A 575/4885SCN3A 610/4885 |
| US-20200046693-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ZELLWEGER SPECTRUM DISORDER | HSD17B4, CYP27A1, OAT | SCN1A 1707/4885SCN2A 2289/4885SCN3A 2390/4885 |
| US-20220152228-A1 | COMPOSITIONS AND METHODS FOR RADIOTHERAPY USING CHELATED RADIOTHERAPEUTIC AGENTS AND NON-TARGET TISSUE BLOCKADE | VDAC1, SLC8B1, CACNA1G | SCN1A 477/4885SCN2A 361/4885SCN3A 317/4885 |
| US-20230000798-A1 | COMPOUNDS AND METHODS OF PROMOTING MYELINATION | GMFG, MAG, SGMS1 | SCN1A 777/4885SCN2A 575/4885SCN3A 610/4885 |
| US-20210315885-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ZELLWEGER SPECTRUM DISORDER | HSD17B4, CYP27A1, OAT | SCN1A 1707/4885SCN2A 2289/4885SCN3A 2390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.